Under the guidance of 21 Invest, a European investment group founded and led by Alessandro Benetton with offices in Italy, France, and Poland, Omega Pharma has completed its first acquisition: Inpha 2000 ("Inpha"), an Italian company active in the research, development, and commercialization of nutraceuticals with a strong scientific rationale. This marks the beginning of the consolidation process of the Italian leader in the dietary supplements sector, which will subsequently aim to grow in the European market, the result of Omega Pharma's ambitious growth path following 21 Invest's entry in January 2024.

Omega Pharma, founded in 1995 in Cantù (Como), is now a benchmark in the nutraceutical market for innovation, quality, and the scientific content of its products. The company specializes in various therapeutic areas, including angiology, gastroenterology, urology, gynecology, ophthalmology, and pediatrics.

Inpha, founded in the early 2000s in Mariano Comense (Como), operates primarily in therapeutic areas complementary to those of Omega Pharma, with a particular focus on cardiology and neurology. Among its flagship products is the Normocis line of supplements, designed to regulate homocysteine levels—an amino acid that, when present in high quantities, increases the risk of cardiovascular diseases such as heart attacks and strokes, as well as neurological disorders. The patented formulation of Normocis has significant growth potential, driven by the medical community's increasing focus on the importance of monitoring homocysteine levels to prevent cardiovascular and neurological conditions.

From a strategic perspective, the acquisition of Inpha represents a unique opportunity to generate significant cross-selling synergies through the integration of sales networks, enabling nationwide coverage for the Normocis line and a broader product range. Moreover, both companies share the same business model, and a sales strategy focused on medical-scientific information, targeting exclusively specialists and general practitioners.

Giuseppe Samaritani and Simone Castelli, founders of Inpha, will remain shareholders by joining the parent company's capital. The current CEO, Marco Pratesi, will continue to lead the company, ensuring managerial continuity.

The synergy between the two companies will create a leading group in the sector, aiming to exceed €30 million in revenue by 2025, with over 150 sales representatives operating nationwide. Sales will be primarily through the pharmacy channel, with a growing contribution from digital channels and international markets.

Alessandro Benetton, Chairman and Founder of 21 Invest, commented: “This transaction marks an important first step in the shared growth journey we are building with Omega Pharma. The goal is to create the Italian leader in the dietary supplements sector, a particularly dynamic market experiencing consolidation both upstream and downstream in the value chain, where Italy plays a leading role at the European level. In this context, the synergies with Inpha lay the groundwork for future development beyond national borders.”

Gianantonio Tomaselli, CEO of Omega Pharma, commented: “Our strategic vision, shared by the founders of Inpha, has brought together two excellent companies to combine forces and accelerate overall growth, becoming an increasingly important reference point in the market, in line with the goals outlined together with 21 Invest.”

Giuseppe Samaritani and Simone Castelli commented: “This transaction represents a great growth opportunity for Inpha, which will find within the group the same focus on innovation and the scientific content of the products that we, as pharmacists, have always had. These are the key factors for sustainable long-term growth.”